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Mitochondrial dysfunction is a hallmark of amyloid-beta(Aβ)-induced neuronal toxicity in Alzheimer’s disease (AD). The recent
emphasis on the intracellular biology of Aβ and its precursor protein (AβPP) has led researchers to consider the possibility that
mitochondria-associated and/or intramitochondrial Aβ may directly cause neurotoxicity. In this paper, we will outline current
knowledge of the intracellular localization of both Aβ and AβPP addressing the question of how Aβ can access mitochondria.
Moreover, we summarize evidence from AD postmortem brain as well as cellular and animal AD models showing that Aβ
triggers mitochondrial dysfunction through a number of pathways such as impairment of oxidative phosphorylation, elevation
of reactive oxygen species (ROS) production, alteration of mitochondrial dynamics, and interaction with mitochondrial proteins.
In particular, we focus on Aβ interaction with diﬀerent mitochondrial targets including the outer mitochondrial membrane,
intermembrane space, inner mitochondrial membrane, and the matrix. Thus, this paper establishes a modiﬁed model of the
Alzheimer cascade mitochondrial hypothesis.
1.Introduction
Although the hallmark lesions of the disease were described
by Alois Alzheimer already in 1906—extracellular amyloid
plaques mainly composed of amyloid-beta (Aβ) and intra-
cellular neuroﬁbrillary tangles (NFTs) built up of hyper-
phosphorylated tau—the molecular mechanisms underlying
the disease are still unknown. However, more recently,
energy deﬁciency and mitochondrial dysfunction have been
recognized as a prominent, early event in Alzheimer’s disease
(AD) [1–11]. Successful development of Alzheimer cell
culture models as well as single, double, and recently triple
transgenic mouse models that mimic diverse aspects of the
disease facilitated the investigation of pathogenic mecha-
nisms in AD and particularly assisted in an understanding
of the interaction of amyloid-beta (Aβ) with mitochondria.
Mitochondria were found to be the target both for amyloid
precursor protein (APP) that accumulates in the mitochon-
drial import channels and for Aβ that interacts with several
proteins inside mitochondria and leads to mitochondrial
dysfunction [12].
2.IntracellularLocalizationofAβPP
Amyloid precursor protein (AβPP) is a type 1 integral
110–130kDa glycoprotein containing a 40 or 42 amino
acid sequence, respectively, called Aβ40 and Aβ42.A βPP
is ubiquitously expressed in human tissues and localizes
at the plasma membrane as well as in several organelles,
such as endoplasmic reticulum (ER), Golgi apparatus, and
mitochondria (Figure 1)[ 13, 14]. AβPP can undergo two
pathways of cleavage by secretases: a nonamyloidogenic
pathway and an amyloidogenic pathway. In the nonamy-
loidogenic pathway, a ﬁrst cut of AβPP is catalyzed by α-
secretase, an enzyme that belongs to the ADAM family of
disintegrin and metalloprotease and is particularly present
in post-Golgi compartment or at the plasma membrane
[15]. α-secretase cleaves AβPP within the Aβ sequence
[16], forming the small membrane-anchored C83 fragment
and sAβPPα. The C83 fragment is subsequently cleaved
by γ-secretase, a multimeric complex of presenilin proteins
PS1 and PS2, nicastrin, anterior pharynx defective1, and
presenilin enhancer 2 [17], to form P3 fragment and AβPP2 International Journal of Alzheimer’s Disease
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Figure 1: Intracellular localization of AβPP and Aβ.A βPP is synthesised in the endoplasmic reticulum (ER) and is traﬃcked through
Golgi network (G), to the cell surface or to mitochondria (Mt). In the plasma membrane the apolipoprotein (Apo) receptor LRP1 forms a
complex with AβPP, inducing the internalization of the amyloid precursor protein, together with other plasma membrane enzymes, such as
the β-secretase BACE and the γ-secretase presenilin (PS): Aβ is produced through amyloidogenic cleavage of AβPP. The plasma membrane
complex AβPP with another Apo receptor, LRP1B, decreases the cellular uptake of AβPP. Sources of mitochondrial Aβ are the endosome
(En) but also G and ER. G production of Aβ is decreased by binding of AβPP to another Apo receptor SorLA that blocks AβPP in the early
G, counteracting AβPP cleavage pathways. Aβ enters into the mitochondrial matrix through TOM and translocase of the inner membrane
(TIM) or is derived from mitochondria-associated AβPP metabolism. N = nucleus, OMM = outer mitochondrial membrane, IMM = inner
mitochondrial membrane.
intracellular domain (AICD) [18, 19]. In the amyloidogenic
pathway, AβPP generates Aβ through the activity of β-
secretase ﬁrst and then γ-secretase, especially present in
Golgi or in late endosomes following the reuptake from
the cell surface. β-secretase whose activity was attributed to
BACE [20] cleaves AβPP at the N-terminal of Aβ sequence
forming a 99 amino acid fragment C99 and sAβPPβ. C99 is
subsequently cleaved by γ-secretase producing Aβ fragment
and AICD [18]. Lipoprotein receptor LRP1 can interact with
AβPP (Figure 1), inﬂuencing AβPP cleavage pathway: the
interaction accelerates endocytosis of the complex AβPP-
LRP1 and the adaptor Fe65 via clathrin-coated pits and the
delivery to the late endosomal compartments for cleavage
by β-secretase, to generate Aβ [21, 22]; this process can
be counteracted by the slower rate of endocytosis LRP1B
that sequestrates AβPP at the plasma membrane, increasing
α-secretase activity [23, 24]. SorLA, a further lipoprotein
receptor, is also involved in AβPP processing by binding
AβPP to the Golgi compartments, impairing the transition
to the plasma membrane and blocking β-secretase activity
(Figure 1)[ 25, 26].
With regard to localization of AβPP in mitochondria,
recent evidence is provided. Mainly the group of Devi and
coworkers [27]demonstratedthatAβPPharboursachimeric
targeting signal consisting of an N-terminal hydrophobic
ER followed by a mitochondrial targeting signal. The
positively charged residues at 40, 44, and 51 of AβPP are
critical components of the mitochondrial targeting signal.
In addition, they showed that AβPP formed stable approx-
imately 480kDa complexes with the translocase of the outer
mitochondrial membrane (OMM) 40 (TOM40) import
channel and a supercomplex of approximately 620kDa with
both mitochondrial TOM40 and the translocase of the
inner mitochondrial membrane 23 (TIM23) import channelInternational Journal of Alzheimer’s Disease 3
TI M23 in an N (in mitochondria)-C (out cytoplasm)
orientation, probably due to a 70 amino acid long acidic
domain [13]. Also in brain tissues of AD aﬀected subjects
AβPP localized with mitochondria fraction, associated to
T OM40andTIM23[27],inatranslocation-arrestedmanner,
t h a tm a yp r e v e n ti m p o r to fde novo synthesised nuclear-
encoded mitochondrial protein, such as subunits of the
electron transport chain (ETC) [27]. Nevertheless, until very
recently [12], it was believed that mitochondrial Aβ has
to arrive from other sources, since AβPP mitochondrial
orientation presents Aβ outside the mitochondria [27].
3.IntracellularLocalizationofAβ
In agreement with the intracellular localization of AβPP, cell
biological studies have demonstrated that Aβ is generated in
the ER, Golgi, and endosomal/lysosomal system (Figure 1).
Reports indicate that Aβx-42(truncated Aβ peptides with
“x” generally ranging from 1 and 11) is preferentially
generated within the ER, whereas Aβ1–40/42 peptides
are predominantly made in the Golgi/trans-Golgi network
(TGN) and packaged into post-TGN secretory vesicles [28,
29]. It is thought that the N-terminal truncation extends
to a maximum length around amino acid 11 which renders
Aβ even more insoluble, the latter pool of Aβ42 not being
secreted [29].
Moreover, mitochondrial accumulation of Aβ has been
shown in AD patient and AβPP transgenic mouse brain
[4, 28, 30]. In transgenic AβPP mice expressing AβPP
V717/F and the AβPP Swedish mutation, mitochondrial Aβ
accumulation increased at around 4 months of age, well
before the formation of plaques [30]. In total, these ﬁndings
are further in line with the recently proposed hypothesis of
an intracellular Aβ toxicity cascade which suggests that the
toxic Aβ species intervening in molecular and biochemical
abnormalities may be intracellular soluble aggregates instead
of extracellular, insoluble plaques [4, 31].
How can Aβ access mitochondria? On the one hand,
Aβ accumulation in mitochondria might derive from the
ER/Golgi (Figure 1), since inhibition of protein secretion
can modulate mitochondrial uptake [30, 32]o rm i g h t
derive from mitochondria-associated AβPP [12]( Figure 1).
It has been hypothesized that oligomeric Aβ, with its sharp
morphology in contrast to monomeric Aβ, has the ability to
permeabilize cellular membranes and lipid bilayers thereby
entering organelles such as mitochondria [33, 34]. Of note,
already early reports about the action of aggregated Aβ on
membranes implicated increased membrane permeability
elicited by ﬁbrils [35, 36]. These mechanisms might explain
why aggregated Aβ preparations elicit eﬀects on mitochon-
drial function, but not disaggregated Aβ. Recent ﬁndings,
however, indicate a speciﬁc uptake mechanism for Aβ by
mitochondria rather than simply being adsorbed to the
external surface of mitochondria [37, 38]. In this model, Aβ
is taken up by mitochondria via the TOM complex. On the
other hand, a new mechanistic view of mitochondria-related
AβPPmetabolismwassuggestedveryrecentlyindicatingthat
AICD, P3 peptide, and potentially Aβ are produced locally at
the mitochondria. Hereby, mitochondrial AβPP is cleaved by
Omi in the intermembrane space and a concerted action of
cytosolic α/β and mitochondrial γ-secretases [12].
4. Mitochondria
Mitochondria are dynamic ATP-generating organelles which
contribute to many cellular functions including intracellular
calcium regulation, alteration of reduction-oxidation poten-
tialofcells,freeradicalscavenging,andactivationofcaspase-
mediatedcelldeath.ATPgenerationisaccomplishedthrough
oxidative phosphorylation [7, 39–42]. ATP is subsequently
used for a large repertoire of functions like intracellular
calcium homeostasis, neurotransmitter production, and
synaptic plasticity. Mitochondrial number is indeed very
high in neurons, and mitochondria are especially enriched in
synapses. Due to the limited glycolytic capacity of neurons,
these cells are highly dependent on mitochondria function
for energy production [43]. However, as the Pandora’s Box,
mitochondria are full of potentially harmful proteins and
biochemical reaction centres. They may liberate reactive
oxygen species (ROS) and free radicals. Thus, mitochondria
are the major producers of ROS and at the same time major
targets of ROS toxicity.
Mitochondria are composed of a double lipid mem-
brane which structures four compartments, distinct by
composition and function. The porous outer membrane
(OMM) encompasses the whole organelle. It contains many
proteins likeimport complexesandvoltage-dependentanion
channels (VDAC) responsible for the free passage of low
molecular weight substances (up to 5000Da) between the
cytoplasm and the intermembrane space (IMS) (Figures 1
and 2) which represents a reservoir of protons establishing
a proton electrochemical gradient across IMM that is needed
fortheproductionofATPviaATPase(complexV).IMScon-
tains proapoptotic proteins like cytochrome c, Smac/Diablo,
EndoG, and Htra2/Omi. In contrast to the permeable
OMM, the inner mitochondrial membrane (IMM), rich
in cardiolipin, provides a highly eﬃcient barrier to the
ﬂow of small molecules and ions, including protons. This
membrane is invaginated into numerous cristae increasing
cell surface area. It houses the respiratory enzymes of the
electron transport chain (ETC), the cofactor coenzyme Q,
and many mitochondrial carriers. In the matrix, diﬀerent
metabolic pathways take place including the tricarboxylic
(TCA or Krebs) cycle (Figure 2).
Mitochondriagenerateenergybytwocloselycoordinated
metabolic processes: TCA and the oxidative phosphorylation
(OXPHOS) (Figure 2). OXPHOS is made up of the ETC
assembled in four enzymes (complex I to IV) as well
as the F1F0-ATP synthase (complex V). Complex I, III,
and IV are located in IMM as integral proteins whereas
complex II is attached to the inner surface of IMM.
These ﬁve enzymes are connected functionally by mobile
electron acceptors and donors: ubiquinone and cytochrome
c. Electrons from NADH and FADH2 are fed into complex
I and II, respectively. Ubiquinone Q carries electrons from
both complexes to complex II, and cytochrome c does
it from complex III to IV reducing molecular oxygen to4 International Journal of Alzheimer’s Disease
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Figure 2: Mitochondrial targets of Aβ.A β associated with mitochondria may be deposited at several locations. Although not present
exclusively on the outer mitochondrial membrane, Aβ that might be present at that site might inﬂuence the interaction of multiple cytosolic
proteins (including those of the bcl2 family) with mitochondria, as well as aﬀect the receptor binding of cargo targeted for import into
the organelle via the TOM import machinery impeding mitochondrial entry to neosynthesised nuclear-encoded proteins such as subunits
of the electron transport chain (ETC) complex IV (CIV). In the intramembrane space, Aβ might aﬀect the functions of both the inner
and outer mitochondrial membrane by multiple mechanisms including modulating their permeability. In the mitochondrial matrix, Aβ
might interact with important components of metabolic or antioxidant mechanisms. The interaction of Aβ with the inner mitochondrial
membrane would bring it into contact with respiratory chain complexes with the potential for myriad eﬀects on cellular metabolism. Thus,
Aβ aﬀects the activity of several enzymes, such as pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (α-KGDH),decreasing
NADH reduction, and the ETC enzyme CIV, reducing the amount of hydrogen that is translocated from the matrix to the intermembrane
space, thus impairing the mitochondrial membrane potential (MMP). The dysfunction of the ETC leads to a decreased CV activity and so to
a lower ATP synthesis, in addition to increasing reactive oxygen species (ROS) production. ROS negatively inﬂuences presequence P (PreP)
activity, blocking Aβ degradation, exacerbating mitochondrial Aβ presence. Moreover, ROS induce peroxidation of several mitochondrial
macromolecules, such as mitochondrial DNA (mtDNA) and mitochondrial lipids, additionally impairing mitochondrial function. Aβ
binds NAD+ pocket in ABAD, blocking its activity and inducing further ROS production. Aβ also inﬂuences mitochondrial dynamic, by
improvingFis1presenceandactivity,thusincreasingmitochondrialfragmentation(ﬁssionprotein:Fis1;fusionproteins:Mfn1/2andOPA1).
Furthermore, Aβ binding to cyclophilin D (CypD) enhances the protein translocation to the inner membrane, favouring the opening of the
mitochondrial permeability transition pore, formed by ANT and VDAC. Calcium storage in mitochondria is impaired, altering neuronal
function; calcium is exported to the cytosol, as well as other apoptotic factors (ProAp) such as cytochrome c, apoptosis-inducing factor,
Smac/DIABLO, endonuclease G, and procaspases, activating cellular apoptosis. IMM: inner mitochondrial membrane, IMS: intermembrane
space, OMM: outer mitochondrial membrane.
water (Figure 2). As electrons are transferred along ETC, a
ﬁxed number of protons are pumped from the matrix into
IMS establishing a electrochemical gradient characterized
with a speciﬁc electrical potential (mitochondrial membrane
potential = MMP: negative inside −150 to −180mV). The
redox energy drives the synthesis of ATP from ADP as
protons are transported back from IMS into the matrix via
complex V.International Journal of Alzheimer’s Disease 5
5. Mitochondrial Targets of Aβ
GrowingevidenceindicatesthatAβtoxicitycanbeassociated
with the outer mitochondrial membrane, intermembrane
space, inner mitochondrial membrane, and the matrix.
5.1. OMM-IMM-IMS
5.1.1. TOM-TIM Import Machinery. A working model pos-
tulates that Aβ and/or AβPP interact with mitochondria
by inhibiting protein import [13, 44]. Import deﬁcits are
initially insuﬃcient to impair mitochondrial integrity but
over time cause mitochondrial dysfunction and further
import deﬁcits. Aβ may inhibit protein import by direct
interactions with the import machinery or by indirect
mechanisms. Given that multiple mitochondrial activities,
including protein import itself, are dependent upon the
import of nuclear-encoded proteins, it seems likely that
even a modest decline in import could have potentially
catastrophic consequences in the long-term. Furthermore, a
decline in protein import seems to precede increased ROS
and decreased mitochondrial membrane potential suggest-
ing a gradual failure of mitochondria. Indeed, recent data
from our group demonstrated mitochondrial dysfunction in
a novel triple transgenic mouse model (pR5/AβPP/PS2)—
tripleAD mice—that combines both pathologic features of
the disease in brain [1]. Using comparative, quantitative
proteomics (iTRAQ) and mass spectroscopy, we found a
massive deregulation of 24 proteins, of which one-third
were mitochondrial proteins mainly related to complexes I
and IV of the oxidative phosphorylation system (OXPHOS).
Notably, deregulation of complex I was taudependent, while
deregulation of complex IV was Aβ dependent, both at
the protein and activity levels. Together, these ﬁndings
emphasize that Aβ and tau synergistically impair complex
I function with aging. Notably, changes in the expression
of complex IV subunits seem to be mainly related to Aβ.
Indeed, a down regulation of several subunits of complex
IV is essentially seen between pR5 and tripleAD mice, but
not between AβPP/PS2 and tripleAD mice. Interestingly, all of
these deregulated proteins are nuclearencoded in agreement
with the assumption of Sirk and coworkers [44].
5.1.2.FusionandFissionProteins. Mitochondriaaredynamic
organelles, undergoing continual ﬁssion, mediated by the
protein Fis1 and dynamin-like protein1 (DLP1), and fusion,
mediated by OPA1, Mfn1, and Mfn2 [45]( Figure 2). Unbal-
anced fusion leads to mitochondrial elongation, and unbal-
ancedﬁssionleadstoexcessivemitochondrialfragmentation,
both of which impair the mitochondrial function [46, 47].
Mitochondrial fusion and ﬁssion have a diﬀerent impact
in mitochondria physiology: ﬁssion allows mitochondrial
renewal, redistribution, and proliferation into synapses
maintaining a pool of healthy mitochondria, while fusion
facilitates mitochondrial movement and distribution across
axons and synapses, suggesting a protective mechanism
helping the maintenance of suﬃcient bioenergetic levels
adjusted to situations with high-energy demands [48–50].
Several ﬁndings indicate that mitochondrial Aβ might
play a role in impaired mitochondrial dynamics [6]. It
could be demonstrated that neuroblastoma cells overex-
pressing human AβPP bearing the Swedish double mutation
(AβPPsw) showed a higher percentage of highly fragmented
and slower mitochondria compared to control cells. More-
over, MMP and ATP produced by mitochondria were
reduced in AβPPsw cells compared to control cells, suggest-
ing vice versa a direct eﬀect of mitochondrial dynamic on
the function of the organelle. In particular, proteins involved
in mitochondrial dynamics were present at diﬀerent levels in
AβPPsw cells compared to control cells. Thus, in AβPPsw
cells, the balance between mitochondrial fusion and ﬁssion
was shifted to enhanced ﬁssion which was accompanied
by increased protein levels of ﬁssion proteins such as Fis-1
and reduced levels of fusion proteins like OPA1 and DLP-
1. In agreement with these in vitro ﬁndings, an abnormal
distribution of mitochondria was also found in pyramidal
neurons of AD-aﬀected individuals [51–53].
Altered mitochondrial dynamics might be due to
enhanced nitrosative stress generated by Aβ,s u c ha sS -
nitrosylationofDLP1.Thismodiﬁcationcandisturbthebal-
ance between ﬁssion and fusion of mitochondria in favour of
mitochondrial ﬁssion followed by mitochondrial depletion
from axons and dendrites and subsequently synaptic loss
[54, 55].
5.2. IMM
5.2.1. ETC: OXPHOS, ATP, and ROS. Early energy dys-
function characterized by a decreased mitochondrial mem-
brane potential, ATP level, and complex IV activity has
been reported for 3- and 6-month-old AβPP transgenic
mice (AβPP; Swedish (KM670/671NL) and London (V717I)
mutation) [3]. These mice showed also increased levels of
4-hydroxynonenal (HNE), a marker of lipid oxidation, and
reduced activity of Cu/Zn superoxide dismutase (SOD) [56].
Interestingly, mitochondrial defects such as the decrease of
complex IV activity in 3-month-old AβPP transgenic mice
were already observed in the absence of plaques, but in the
presenceofincreasedAβ levelsinbrain[3,57].Furthermore,
an age-dependent impairment of oxygen consumption such
as a decrease of state 3 and uncoupled respiration were
observed in AβPP transgenic mice compared to age-matched
controls [3, 30, 58]. In addition, AβPP/PS1 transgenic mice,
w h i c hi nc o n t r a s tt oA βPP transgenic mice exhibit Aβ
plaques already at an age of 3 months, presented stronger
reductions in mitochondrial membrane potential and ATP
levelscomparedtoage-matchedAβPPtransgenicmice.Con-
sequently, Aβ-dependent mitochondrial dysfunction starts
already at a very young age and accelerates substantially with
increasing age as does Aβ plaque load [59].
The development of sophisticated proteomic methods
allowed the examination of synaptosomal fractions from
AβPP transgenic mice (Tg2576) and revealed a massive
neuronal decay and synapse loss as the ﬁnal consequence
from all pathological changes occurring in AD [18]. Addi-
tional studies revealed signiﬁcant diﬀerences in mitochon-
drial hsp70 and protein subunit composition of respiratory6 International Journal of Alzheimer’s Disease
chain complexes I and III in this transgenic mouse model
[58].
In a new tripleAD (pR5/AβPP/PS2) mouse model, we
showed ﬁrst of all that Aβ and tau act synergistically in
amplifying mitochondrial respiratory deﬁcits, mainly of
complex I and IV activities. Thereby, hyperphosphorylated
tau may drive a vicious cycle within the Aβ cascade.
Remarkably, deregulation of complex I was related to tau,
whereas deregulation of complex IV was Aβ dependent, both
at the protein and activity levels. The synergistic eﬀects of Aß
and tau led already at the age of 8 months to a depolarized
mitochondrial membrane potential in the tripleAD mice.
Additionally, we found that age-related oxidative stress at
12 months of age may exaggerate the dysfunctional energy
homeostasis and synthesis of ATP and, in turn, take part in
the vicious cycle that ﬁnally leads to cell death [60]. Our
data complement those obtained in another triple transgenic
mouse model 3xTg-AD (P301Ltau/AβPP/PS1) [61]. Yao
and colleagues described age-related bioenergetic deﬁcits in
female 3xTg-AD mice aged from 3 to 12 months [62]. They
found a decreased activity of regulatory enzymes of the
OXPHOS (pyruvate dehydrogenase (PDH) and cytochrome
c oxidase(COX))andincreasedoxidativestressandlipidper-
oxidation. Most of the eﬀects on mitochondria were seen at
the age of 9 months, whereas mitochondrial respiration was
signiﬁcantly decreased with 12 months of age. Importantly,
mitochondrial bioenergetic deﬁcits precede the development
of AD pathology in the 3xTg-AD mice.
5.2.2. Cyclophilin D. Mitochondrial Aβ may interact with
Cyclophilin D (CypD), an integral part of the mitochondrial
permeability transition pore (mPTP) which potentiates free
radical production, causes synaptic failure, and promotes the
opening of the mPTP leading to apoptosis [63].
CypD, a peptidylprolyl isomerase F, normally resides
in mitochondrial matrix and is involved in apoptosis and
necrosis. It has been demonstrated that CypD is able to form
complexes with Aβ within mitochondria of cortical neurons
from APP transgenic mice, increasing the translocation of
CypD from the matrix to the inner membrane (Figure 2)
[64]. The translocation of CypD represents a ﬁrst step in
the opening of mPTP and involves the binding of CypD
with adenine nucleotide translocase [65–69]. mPTP opening
can lead to matrix swelling, dissipation of the inner mem-
brane potential, and generation of ROS, with subsequent
rupture of the outer membrane and a nonspeciﬁc release
of intermembrane space proteins into the cytosol, such
as cytochrome c, apoptosis-inducing factor, Smac/DIABLO,
endonuclease G, and procaspases, that will activate several
signal transduction pathways such as apoptosis [70–75].
Furthermore, in AβPP transgenic mice the abrogation
o fC y p Dw a sa b l et oa t t e n u a t eA β-mediated abnormal
mitochondrial dysfunction, such as calcium-induced mito-
chondrial swelling, lowered mitochondrial calcium uptake
capacity, and impaired mitochondrial respiratory function
[64]. Moreover, a correlation was found between levels of
CypD in mitochondria and resistance to the opening of
mPTP induced by calcium [76, 77], further supporting an
active role of CypD in neuronal loss caused by Aβ.
5.3. Matrix
5.3.1. The Tricarboxylic Acid Cycle (TCA or Krebs Cycle).
Impairmentintheactivityandlevelsofseveralmitochondria
enzymes involved in the Krebs cycle was reported since the
early 80’s (Figure 2). Perry and colleagues observed a reduc-
tion in pyruvate dehydrogenase (PDH), ATP-citrate lyase,
and acetoacetyl-CoA thiolase in postmortem brain tissues
of AD-aﬀected subjects and correlated the decrease of these
enzymes to the decreased production of acetylcoenzyme A
and cholinergic defects that are observed in AD [78]. A
frontal cortex deﬁciency in PDH activity was also observed
in another cohort of brain tissues from AD patients [79].
Moreover, a reduced activity of thiamine-pyrophosphate-
dependent enzymes, such as α-ketoglutarate dehydrogenase
(KGDH), was observed in brain tissues [80, 81]a sw e l la s
i np e r i p h e r a lc e l l sf r o mA Ds u b j e c t s[ 81, 82]. The brain’s
reduction in α-ketoglutarate dehydrogenase presence and
a c t i v i t yw a sr e g i o ns p e c i ﬁ ca n do b s e r v e dm a i n l yi nt e m p o r a l
cortex, parietal cortex, and hippocampus [83]. Very inter-
estingly, the loss of α-ketoglutarate-dehydrogenase-positive
neurons could be correlated to the total loss of neurons,
suggesting a possible reason for the selective vulnerability
in AD brain [84]. In the central nervous system, the high
metabolic demand can lead to a higher level of oxidative
stressviatheproductionoffreeradicals.KGDHissensitiveto
a wide range of oxidants. Under pathological conditions, Aβ
furtherincreasesoxidativestressleadingdirectlyorindirectly
to a decline in the activity of KGDH [85, 86].
5.3.2. ABAD. The involvement of mitochondria in the
pathogenic pathway of Aβ was conﬁrmed by speciﬁc binding
of Aβ and AβPP to mitochondrial proteins which causes
energy impairment and cell physiology defects. Firstly,
Aβ speciﬁcally binds to the mitochondrial Aβ-binding
alcohol dehydrogenase (ABAD) [4], a mitochondrial matrix
protein which is upregulated in the temporal lobe of AD
patients as well as in AβPP transgenic mice [87–89]. The
Aβ-ABAD interaction caused elevated reactive oxygen
species (ROS) production and cell death as well as spatial
learning and memory deﬁcits in 5-month-old AβPP/ABAD
double-transgenic mice. The investigation of the crystal
structure of ABAD-Aβ demonstrated that the formation
of the complex prevents the binding of NAD+ to ABAD,
thereby changing mitochondrial membrane permeability
[90] and reducing the activities of respiratory enzymes [4]
which then may lead to mitochondrial failure. ABAD, a
member of the short-chain dehydrogenase/reductase family,
shows enzymatic activity toward a broad array of substrates
including n-isopropanol and beta-estradiol. Thus, ABAD
is important for mitochondrial function via facilitation
of ketone body utilization by promoting the generation
of acetyl-CoA to feed into the TCA cycle, an eﬀect that is
particularly important in situations of stress.
5.3.3. mtDNA. Some of the alterations that are found in
mitochondrial function in AD have been attributed to
mutations of mtDNA [91]. Although most mitochondrialInternational Journal of Alzheimer’s Disease 7
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Figure 3: A hypothetical sequence of the pathogenic steps of the Alzheimer mitochondrial cascade hypothesis. The main cytotoxic pathway
of Aβ (red arrows) involves Aβ-induced mitochondrial function, increased ROS production, activation of neuroﬁbrillary tangles (NFT)
formation, synaptic failure, and neurodegeneration. Several other pathways feed this cascade via feeding back (black arrows) or forward
(dashed arrows) revealing several vicious cycles within a larger vicious cycle. All of them, once set in motion, amplify their own processes,
thus accelerating the development of AD.
proteins are encoded by the nuclear genome, mitochondria
contain many copies of their own DNA that encodes for
13 polypeptide complexes of the respiratory chain. The
increased number of mtDNA mutations can be explained
by the proximity of mtDNA to oxidative stress generated
by the respiratory chain itself, the lack of mtDNA to any
protective histone covering, and a deﬁcient repair mecha-
nism compared to nuclear DNA. Therefore, mitochondria
themselves are extremely sensitive to oxidative stress. For
instance, mtDNA np4336 mutation in the tRNAGln gene
was reported in sporadic AD patients [91–95]. In addition,
it was shown that AD brains exhibited a striking increase
in a 1,112-np mtDNA control region, an element known
to be involved in mtDNA transcription and/or replication
[96]; mutations in this region may be responsible for a
decreasednumberofmitochondria.Inthelightofthesedata,
a mitochondria cascade hypothesis was developed to explain
the prevalence of AD by hypothesising that the pathology
will easily develop when a mitochondria starting line, in
conjunctionwithgeneticandenvironmentalfactors,exhibits
increased mtDNA mutations (Figure 3).
5.3.4. PreP. Several enzymes were identiﬁed to degrade Aβ.
Neural endopeptidase (NEP) was shown responsible for
the extracellular degradation of Aβ [97], while the two
members of the pitrilysin oligopeptidase family, human
insulin degrading enzyme (IDE) and presequence protease
(PreP), are responsible for the intracellular degradation of
Aβ. PreP is a metalloprotease containing an inverted zinc-
binding motif and was ﬁrst identiﬁed in Arabidopsis thaliana
as the enzyme responsible for mitochondrial degradation of
targeting peptides up to 65 amino acids [98–100]. Intrami-
tochondrial localization studies demonstrated PreP to be
localizedwithinthemitochondrialmatrix[101,102].Incase,
Aβ reaches the matrix, it can be degraded by PreP (Figure 2).
Two highly conserved cysteines (Cys527 and Cys90) are
able to form a disulphide bridge in oxidizing condition,8 International Journal of Alzheimer’s Disease
locking PreP in an inactive form. Since oxidizing conditions
are present with high amount of Aβ in mitochondria, this
may prevent the clearance of Aβ (Figure 2), exacerbating
mitochondrial dysfunctions by accelerating its interactions
with CypD and/or ABAD [37].
6. Conclusion
Rigorous scientiﬁc research has identiﬁed multiple mecha-
nisms of Aβ interaction with mitochondria at diﬀerent mito-
chondrial compartments: the outer mitochondrial mem-
brane, intermembrane space, inner mitochondrial mem-
brane, and the matrix. With regard to the involvement of
Aβ-induced mitochondrial dysfunction in AD pathogenesis,
av i c i o u sc y c l ea sw e l la ss e v e r a lv i c i o u sc i r c l e sw i t h i nt h e
cycle, each accelerating the other, can be drawn emphasizing
the Alzheimer mitochondrial cascade hypothesis (Figure 3).
AβPP and/or Aβ may block mitochondrial translocation of
nuclear-encoded proteins [27], such as components of the
ETC [103–106], impairing mitochondrial function. Intrami-
tochondrial Aβ is able to perturb mitochondrial function in
several ways by directly inﬂuencing ETC complex activities
[1],impairingmitochondrialdynamics[6]ordisturbingcal-
cium storage [107, 108], thus increasing apoptotic pathways
[64], as well as via interaction with CypD. Moreover, Aβ
interacts with mitochondrial matrix components, such as
enzymesoftheKrebscycle[109]andABAD[87,110],aswell
as PreP [37]. An improper mitochondrial complex function
leads to a decreased mitochondrial membrane potential of
the organelle [111], impairing ATP formation [3, 59, 112–
118]. Increased ROS levels act at multiple levels to impair
mitochondrial function: they induce mtDNA mutations
[91] that consequently negatively inﬂuence mitochondrial
function [119], enhance Aβ production by guiding AβPP
cleavage pathway toward the amyloidogenesis [120], increase
lipid peroxidation [121, 122], activate mitophagy [123],
leading to a reduced mitochondrial number [123], and
augment tau hyperphosphorylation and NFT formation
impairing organelle traﬃcking and neuronal function ﬁnally
leading to apoptosis.
Finally, the critical role of mitochondria in the early
pathogenesis of AD may make them attractive as a prefer-
ential target for treatment strategies. Transgenic mice mod-
elling some pathological aspects are hence very valuable in
monitoring therapeutic interventions at the mitochondrial
level. In agreement, recent data suggest that natural plants
such as a standardized Ginkgo biloba extract or the green
tea component epigallocatechin-3-gallate may be promising
treatment strategies. Of note, in addition to their antiox-
idative properties, these compounds stabilize mitochondrial
functions such as the mitochondrial membrane potential,
ATP levels, and mitochondrial respiratory complexes [124–
127]. Moreover, in APP transgenic mouse models, an
antiamyloidogenic eﬀect of these compounds was reported
by inhibiting amyloid ﬁbril formation either by a direct
interaction with Aβ [128, 129] or indirectly by reducing ROS
levels [127]. However, the precise actions and, in particular,
the mitochondrial targets of these drugs at the molecular
level are unclear and need further clariﬁcation. In view
of the increasing interest in mitochondrial protection as
a treatment strategy in dementia, besides strategies with
regard to the treatment and/or removal of both Aβ and
tau pathology, the ﬁndings of a substantial protection
of mitochondria against Aβ-induced dysfunction deserve
further attention.
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